The Department of Surgery at the University of Texas Medical School at Houston
Department of Surgery
MHH Life Flight

Faculty Biography

Department of Surgery,
Division of Acute Care Surgery


Nena Matijevic (Aleksic), Ph.D.

Associate Professor, Research
Division of Acute Care Surgery,
Department of Surgery,
The University of Texas Medical School at Houston

Center for Translational Injury Research (CeTIR)

Back

Education:

UNDERGRADUATE

1969-1974 University of Belgrade, Faculty of Pharmacy, Belgrade, Yugoslavia.
Degree: Pharm.D.

GRADUATE

1983-1986 University of Belgrade, Medical School, Belgrade, Yugoslavia.
Degree: M.S. in Medical Sciences – Hematology
Thesis: “Platelet functions in patients with idiopathic thrombocytopenic purpura (ITP).”

POSTGRADUATE

1986-1988 University of Belgrade, Faculty of Pharmacy, Belgrade, Yugoslavia
Degree: Specialist in Medical Biochemistry
Thesis: “Protein C activity in patients on oral anticoagulant therapy”

DOCTORAL STUDIES:

1996-1998 University of Belgrade, Medical School, Belgrade, Yugoslavia
Degree: Ph.D. in Medical Sciences - Hematology
Dissertation: “Expression of prostaglandin H2 synthase and thromboxane A2 synthase in megakaryocytes and platelets”

ACADEMIC APPOINTMENTS

1974 - 1975 Regular one year pharmaceutical practice, Belgrade City Hospital Pharmacy, Belgrade, Yugoslavia

1975 - 1976 Central Clinical Chemistry Laboratory, Belgrade City Hospital, Belgrade, Yugoslavia

1976 - 1988 Hemostasis Laboratory Supervisor, Belgrade City Hospital, Belgrade, Yugoslavia

1988 - 1992 Hemostasis Laboratory Manager, University Clinical Center, Department of Hematology, Belgrade, Yugoslavia

1992 - 2000 Research Instructor, University of Texas Houston Health Science Center, Medical School, Internal Medicine, Hematology and Vascular Biology Research Center, Houston, Texas

1996 - 2005 ARIC (Atherosclerosis Risk in Communities) Central Hemostasis Laboratory Manager, University of Texas Houston Health Science Center, Medical School, Internal Medicine, Hematology, Houston, Texas

2000- 2007 Assistant Professor in Medicine (research), University of Texas Houston Health Science Center, Medical School, Internal Medicine, Hematology and Vascular Biology Research Center, Houston, Texas

2001- Present ARIC Flow Cytometry Laboratory Director, University of Texas Houston Health Science Center, Medical School, Internal Medicine, Hematology and Vascular Biology, Houston, Texas

2007- Present Associate Professor in Medicine (research), University of Texas Houston Health Science Center, Medical School, Internal Medicine, Hematology and Vascular Biology Research Center, Houston, Texas

2008 - Present Associate Professor (Research), University of Texas Medical School at Houston, Department of Surgery, Center for Translational Injury Research, Houston, Texas

PROFESSIONAL ORGANIZATIONS:

American Society of Hematology (ASH)

International Society on Thrombosis and Haemostasis (ISTH), Clinical Cytometry Society (CCS), Mediteranian League against Thromboembolic Disease (MLTD)

COMMITTEES:

1996–2005 Laboratory Committee of Atherosclerosis Risk in Communities (ARIC) Study, National Heart Lung and Blood Institute

2004– Present Laboratory Committee of the ARIC Carotid MRI Study, National Heart Lung and Blood Institute

2005– Present Quality Control Committee of the ARIC Carotid MRI Study, National Heart Lung and Blood Institute

EDITORIAL POSITIONS:

Reviewer for the Circulation journal
Reviewer for the Journal of Neurology
Reviewer for the Journal of Thrombosis and Hemostasis
Reviewer for the ARIC Publication Committee
Reviewer for the CHS (Cardiovascular Health Study) Publication Committee

TEACHING RESPONSIBILITIES:

Training and supervising laboratory personnel and Hematology/Oncology fellows who rotate through laboratories, laboratory practice and current research approaches and procedures in hemostasis, platelet functions, blood cell receptors, prostaglandins .

GRANT SUPPORT:

“Atherosclerosis, Plaque and CVD in Communities”. Role: PI of the cellular studies of this U01grant; PI: Eric Boerwinkle, SPH. U01 HL075572, NIH/NHLBI, 9/15/04 – 6/30/08 ($15,514,165).
The aim of the project is to identify and correlate cellular and inflammatory processes contributing to atherosclerotic plaque development and changes in the vascular wall, and therefore potential modifying mechanisms.

PAST GRANT SUPPORT:

“Atherosclerosis Risk in Communities (ARIC) Study: Morbidity/Mortality Follow-up”: Central Hemostasis Laboratory. Role: Co-investigator; PI: Kenneth K Wu. N01-HC55022, NIH/NHLBI, 9/1/85 – 01/31/06 ($10,241,474). The ultimate goal was to identify hemostatic factors and their genetic polymorphisms that predict risk for atherosclerosis progression and development of coronary heart disease and ischemic stroke.

“Epidemiology of Venous Thrombosis and Pulmonary Embolism”, University of Minnesota SPH, Role: Co-Investigator; PI: Aaron R Folsom. R01 HL59367, 02/01/98 – 01/31/02 .The overall objective of this study was to investigate the etiology and identify risk factors prospectively for venous thromboembolism, comprising deep venous thrombosis and pulmonary embolism, in defined populations of African-American and white men and women.

“Prostaglandins in Cerebral Vascular Thrombosis”, Role: Core Lab Co-Investigator. PI: Kenneth K Wu. P 50 NS-23327, NIH/NHLBI, year 17-21, 04/1999 – 3/30/2004.

PUBLICATIONS:

Abstracts
  1. Pendic B, Matijevic N, Plecas V, Dragovic M. Effects of cytostatics commonly used for treatment of acute leukemia on platelet aggregation in vitro. 6th Meeting of Yugoslav Society of Hematology and Transfusiology, Portoroz. Abstract book. 1976.
  2. Matijevic N, Pendic B, Zdravkovic M, Ivankovic D. The effect of aspirin on platelet aggregation in vivo and in vitro. VII Yugoslav Congress of Pharmacy, Ohrid, Abstracts. p.80. 1976.
  3. Matijevic N, Sisic I, Korolija P, Pendic B. Estimation of hemostasis in elderly subjects treated with Complamin®. I Yugoslav Congress of Gerontologists, Belgrade, Abstract book. 1977.
  4. Zdravkovic M, Matijevic N, Ivankovic D, Pendic B, Tubin M, Cvetkovic G. Platelet aggregation and gastrointestinal complications during the treatment of rheumatic fever with aspirin. XV Meeting of Internists, Symposium "Drugs and Health", Subotica. Abstract book. 1977.
  5. Matijevic-Aleksic N, Pajevic M, Milutinovic Dj, Tomasevic R, Pendic B. The influence of platelet storage and temperature on platelet functions. III Yugoslav Congress of Hematology and Transfusiology, Sarajevo, 1978. Abstracts, p.153-154.
  6. Jelic S, Bojic M, Dragovic M, Miletic V, Matijevic N, Plecas V. Leukemic phase of diffuse histiocytic lymphoma (Reticulum Cell Sarcoma). III Yugoslav Congress of Hematology and Transfusiology, Sarajevo. Abstracts, p.123-124. 1978.
  7. Pajevic M, Matijevic N, Jelic S, Djuric D, Pendic B, Plecas V. Investigation of immunological and hemostatic parameters related to platelets transfusion in patients with malignant hemopathies. III Yugoslav Congress of Hematology and Transfusiology, Sarajevo. Abstracts, p.151-152. 1978.
  8. Miletic V, Jelic S, Gligorovic V, Matijevic N, Plecas V. Physicochemical properties and biologic effects of commercial gamma globulin preparations. III Yugoslav Congress of Hematology and Transfusiology, Sarajevo. Abstracts p.159-160. 1978.
  9. Pendic B, Matijevic N. Cytostatics and platelet aggregation. III Yugoslav Congress of Hematology and Transfusiology, Sarajevo. Abstracts, p.230-231. 1978.
  10. Savic S, Zdravkovic M, Najdanovic B, Ivankovic D, Ristic V, Madic R, Dimitrijevic I, Djordjevic G, Matijevic N. Les effets du Propranolol (Inderal) sur l' hypertension arterielle chez les malades avec des valeurs elevees de l' activite de la renine plasmatique. VII Congress International de Pharmacologie, Paris, France, 1978.
  11. Savic S, Zdravkovic M, Najdanovic B, Ivankovic D, Djordjevic G, Matijevic N. The activity of plasma rennin and aldosterone in the essential hypertension and the effects of Propranolol on the former. International Symposium on Essential Hypertension, Herceg Novi, 1978.
  12. Matijevic N, Miletic V, Pendic B. Characteristics of platelet aggregation induced by heat-aggregated immunoglobulins. VI Yugoslav Symposium of Immunology, Tara, 1979.
  13. Matijevic N, Miletic V, Pendic B. Aggregation of human blood platelets with monomeric and aggregated immunoglobulins. II Meeting of Yugoslav Society of Hemostasis and Thrombosis, Belgrade, 1979.
  14. Jelic S, Matijevic N, Miletic V. Platelet aggregation in vitro in the presenceof mixed IgG and IgM cryoglobulins. II Meeting of Yugoslav Society of Hemostasis and Thrombosis, Belgrade, 1979.
  15. Matijevic N, Petrovic M, Vidakovic B, Plecas V, Pendic B. Platelet function in cytostatics treated patients. VII Meeting of Yugoslav Society of Hematology and Blood Transfusion, Split, 1980.
  16. Pendic B, Matijevic N, Dimitrijevic B, Pantic V. Action des agents da la chimiotherapie sur l’ aggregation plaquettaires in vitro. 18th International Congress of the Society of Hematology, Montreal, Canada. Abstract 1197, 1980.
  17. Milenkovic Lj, Tomasevic R, Djuric D, Radovic M, Matijevic N. Comment on certain platelet preparation procedures for transfusion. Symposium "Current problems in health care of hematologic patients", Belgrade, 1980.
  18. Matijevic-Aleksic N, Pendic B. Clinical use of platelet aggregation studies. VI Yugoslav Congress of Clinical Chemistry, Split, 1983.
  19. Pudar-Brankovic G, Matijevic-Aleksic N, Peric Lj, Mijalkovic D, Brankovic S. Platelet aggregation in patients with diabetes mellitus. Yugoslav Congress of Endocrinology, Novi Sad, 1984.
  20. Matijevic-Aleksic N, Rolovic Z, Pendic B. Platelet function in patients with idiopathic thrombocytopenic purpura. IV Yugoslav Congress of Hematology and Transfusiology, Skoplje, 1984.
  21. Despotovic N, Paranos S, Matijevic-Aleksic N, Rosic D. Platelet aggregation abnormalities in patients with elevated IgE. Scientific Meeting of Serbian Academy of Sciences and Art, Division of Medical Sciences, "Specific Hypersensitivity of the Organism", Belgrade. Abstract book.1986.
  22. Matijevic-Aleksic N, Petrovic M, Rajic M,Vidakovic B. Antithrombin III in patients with malignant hemopathies. V Yugoslav Congress of Hematology and Transfusiology, Maribor. Abstracts. 1986.
  23. Matijevic-Aleksic N, Rolovic Z. Platelet aggregation in patients with idiopathic thrombocytopenic purpura. V Yugoslav Symposium on Hemostasis and Thrombosis, Novi Sad. Abstract book. 1987.
  24. Matijevic-Aleksic N, Jovic B, Paranos S, Despotovic N. Influence of elevated concentrations of serum IgE on human platelet aggregation. 7th Yugoslav Congress of Clinical Chemistry, Novi Sad. Abstract book.1987.
  25. Matijevic-Aleksic N, Petrovic M, Jovic B, Rajic M, Vidakovic B. Hemostasis inhibitors in patients with malignant hemopathies. VII Yugoslav Congress of Cancer, Novi Sad. Abstract book. 1987.
  26. Petrovic M, Matijevic-Aleksic N, Plecas V, Radulovic S. Hemostasis abnormalities in malignant diseases. XXIV Meeting of Oncology and Radiology, Belgrade, 1987.
  27. Matijevic-Aleksic N, Jelic Z, Majkic-Singh N. Protein C and oral anticoagulant therapy. II Dalmatian Meeting of Clinical Chemistry, Split. Abstract book. 1988.
  28. Starcevic D, Matijevic-Aleksic N, Jelic-Ivanovic Z. C1-esterase inactivator in malignant diseases. II Dalmatian Meeting of Clinical Chemistry, Split. Abstract book. 1988.
  29. Matijevic-Aleksic N, Petrovic M, Plecas V, Vidakovic B, Panajotovic-Jovic B. Comparison of hemostatic parameters in patients with malignant diseases. IX Meeting of Yugoslav Society of Hematology and Transfusiology, Novi Sad. Abstracts. 1988.
  30. Matijevic N, Elezovic I, Rolovic Z. Plasma levels of thrombin-antithrombin (TAT) complex in patients with acute leukemia. VI Yugoslav Meeting of Society of Hemostasis and Thrombosis, Ljubljana. Abstracts. 1990.
  31. Matijevic N, Elezovic I, Rolovic Z. Plasma levels of fibrinogen and fibrin degradation products in patients with acute leukemia. VI Yugoslav Meeting of Society of Hemostasis and Thrombosis, Ljubljana. Abstracts. 1990.
  32. Elezovic I, Matijevic N, Rolovic Z. Plasma levels and activities of factor XIII in patients wuth acute leukemia. VI Yugoslav Meeting of Society of Hemostasis and Thrombosis, Ljubljana. Abstracts. 1990.
  33. Matijevic-Aleksic N, Boskovic D, Rolovic Z. Control of oral anticoagulant therapy using two different thromboplastins. 11th International Congress on Thrombosis, Ljubljana. Abstracts.1990.
  34. Matijevic-Aleksic N, Jelic-Ivanovic. Functional assay of Protein C in patients on oral anticoagulant therapy. 11th International Congress on Thrombosis, Ljubljana. Abstracts.1990.
  35. Matijevic-Aleksic N, Elezovic I, Marisavljevic D, Colovic M, Rolovic Z. Thrombin-antithrombin III complex in acute leukemia. 6th Yugoslav Congress of Hematology and Transfusiology, Zagreb. Bilten Hematol Transf 17:110, 1990
  36. Elezovic I, Matijevic N, Boskovic D, Mijovic A, Tomin D, Colovic M, Novak A, Rolovic Z. Disseminated intravascular coagulation in patients with acute promyelocytic leukemia. 6th Yugoslav Congress of Hematology and Transfusiology, Zagreb, 1990, Bilten Hematol Transf 17:109, 1990
  37. Matijevic-Aleksic N, Elezovic I, Rolovic Z, Dimcic Z, Stefanovic Lj. Laboratory manifestation of a lupus-like anticoagulant: case report. VIII Yugoslav Scientific Meeting of Alergology and Clinical Immunology, Kopaonik. Abstracts. 1990.
  38. Matijevic-Aleksic N, Dimcic Z, Rolovic Z. Protein C and Protein S in systemic diseases. VIII Yugoslav Scientific Meeting of Alergology and Clinical Immunology, Kopaonik. Abstracts. 1990.
  39. Elezovic I, Matijevic-Aleksic N, Jane`ic A., Markovic Lj., Bonaci-Nikolic B., Djordjevic S. Anticardiolipin antibodies in patients with immune thrombocytopenic purpura. VIII Yugoslav Scientific Meeting of Alergology and Clinical Immunology, Kopaonik. Abstracts. 1990.
  40. Dimcic Z, Bukulica M, Djordjevic S, Matijevic-Aleksic N, Markovic Lj, Tanurdcic S, Djuric M. Hemostatic abnormalities in patients with systemic lupus erythematosus associated with a presence of anticardiolipin antibodies. VIII Yugoslav Scientific Meeting of Alergology and Clinical Immunology, Kopaonik. Abstracts. 1990.
  41. Dimcic Z, Bonaci-Nikolic B, Markovic Lj, Matijevic-Aleksic N, Balaban J, Tanurdcic. A case of cerebral systemic lupus erythematosus associated with anticardiolipin antibodies. VIII Yugoslav Scientific Meeting of Alergology and Clinical Immunology, Kopaonik. Abstracts. 1990.
  42. Elezovic I, Matijevic-Aleksic N, Marisavljevic D, Suvajdic N, Rolovic Z. Fibrinolysis and fibrinogenolysis in acute leukemia. XIIIth Congress of the International Society on Thrombosis and Haemostasis, Amsterdam. Thromb Haemostas 65:895. 1991.
  43. Matijevic-Aleksic N, Elezovic I, Suvajdic N, Rolovic Z. Levels of fibrinopeptide A and thrombin-antithrombin III complex in patients with acute leukemia. XIIIth Congress of the International Society on Thrombosis and Haemostasis, Amsterdam. Thromb Haemostas 65:1322. 1991.
  44. Matijevic-Aleksic N, Dulic B, Rolovic Z. Markers of hemostasis activation after total hip replacement. 12th International Congress on Thrombosis, Florence, Italy. Abstracts P353.1992.
  45. Simic N, Avramovic D, Matijevic-Aleksic N, Stevic S, Kalimanovska-Ostric D. Indobufen treatment of angina pectoris: effects on platelet aggregation. International meeting in Cardiology, Amsterdam.Abstracts.1992.
  46. Aleksic, N. M., Sanduja, S. K., Long, C., Wu, K. K. Coordinate expression of prostaglandin H synthase and thromboxane A synthase in phorbol-induced differentiation of a megakaryocyte cell line (MEG-01). 35th Annual Meeting ,The American Society of Hematology, St. Louis, MO, December 3-7. Blood, 82:suppl.1. 266. 1993.
  47. Wu, K.K., Sanduja, S.K, Tsai, A.-L., and Matijevic-Aleksic, N. Quantitative analysis of prostaglandin H synthase (PGHS-1) decay in cells overxpressing PGHS-1. 9th International Conference on Prostaglandins and Related Compounds, Florence, Italy, June 6-10. Abstract, p.76.1994.
  48. Elezovic, I., Matijevic-Aleksic, N., Boskovic, D., Colovic, M., Mijovic, A.S., Tomin, D., Mijovic, A.M., Suvajdic, N., Vidovic, A., Rolovic, Z. Disorders of hemostasis in acute leukemia. 1st Yugoslav Hematology Congress, Belgrade, Yugoslavia, October 1994. Bilten Hematol 22:86, 1994.
  49. Elezovic, I., Matijevic-Aleksic, N.,Colovic, M.,. Boskovic, D., Mijovic, A.S., Tomin, D., A.M. Mijovic, Suvajdic, N., Maric, A., Rolovic, Z. Disseminated intravascular coagulation in acute leukemia. 1st Yugoslav Hematology Congress, Belgrade, Yugoslavia, October 1994. Bilten Hematol 22:87.1994.
  50. Matijevic-Aleksic, N, Ghaddar, H., McPhedran, P., Wu, K.K. Bleeding disorder due to platelet cyclooxygenase-1 (COX-1) deficiency. 36th Annual Meeting, American Society of Hematology, Decembar 2-6, 1994, Nashville, TN. Blood. 84:suppl.1. 1267.1994.
  51. Elezovic, I., Matijevic-Aleksic, N., Rolovic, Z. Elastase -1 proteinase inhibitor complexes in acute leukemia. XV Congress of the International Society on Thrombosis and Haemostasis, Jerusalem, Israel, June 11-16, 1995. Thromb Haemost 73:1146. 1995.
  52. Matei, M.C., Aleksic, N., Ahn, C., Wu, K.K., Juneja, H.S. Hemostasis activation markers in sickle cell disease: association with painful crisis. 38th Annual American Society of Hematology Meeting, Orlando, Florida, December 6-10, 1996. Blood. 88: suppl 1;2803.
  53. Elezovic I, Pilic Z, Nedeljkovic N, Marisavljevic D, Matijevic-Aleksic N, Miljic P, Radosevic N, Todorovic-Tirnanic M: Caesare section in a case with Bernard-Suilier syndrome. X Yugoslav Hematology Days with International Participation, Niska Banja, October 10-12, 1996. Abstract Book. 122. 1996.
  54. Elezovic I, Matijevic-Aleksic N, Rolovic Z: The role of elastase in coagulation disorders of acute leukemia patients. X Yugoslav Hematology Days with International Participation, Niska Banja, October 10-12, 1996. Abstract Book. 125.1996.
  55. Ghaddar, H.M., Aleksic, N., Hearne, L.B., Folsom, A.R., Chambless, L.E., Morrissey, J.H., Wu, K.K. The ARIC postprandial study: relation of factor VII with factor VII gene polymorphism and triglyceride levels in carotid atherosclerosis cases and controls. XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, June 6-12, 1997. Thromb Haemost Suppl, 413.1997.
  56. Folsom, A.R., Rosamond, W.D., Shahar, E., Cooper, L.S., Aleksic, N., Nieto, F.J., Rasmussen, M., Wu, K.K. Prospective study of markers of hemostatic function, inflammation, and endothelial function with risk of ischemic stroke. Abstract 1072. 71st Scientific Session of the American Heart Association, November 8-11, 1998, Dallas, Texas. Circulation, Suppl I, 98:17:207.1998.
  57. Salomaa, V., Matei, V., Aleksic, N., Sansores-Garcia, L., Folsom, A.R., Juneja, H., Chambless, L.E., Wu, K.K. Soluble thrombomodulin as a predictor of incident coronary heart disease: The ARIC study. Abstract 2756. 71st Scientific Session of the American Heart Association, November 8-11, 1998, Dallas, Texas. Circulation. Suppl I, 98:17:524. 1998.
  58. Aleksic, N., Juneja, H., Folsom, A.R., Ahn, C., Boerwinkle, E., Chambless, W., Wu, K.K. Prospective study of platelet PlA1/A2 polymorphism, platelet activation and incidence of coronary heart disease. The 40th American Society of Hematology Annual Meeting, Miami Beach, Florida, December 4-8, 1998. Blood 92 (suppl 1): 304a, 1998
  59. Wu KK, Aleksic N, Ahn C, Boerwinkle E, Folsom A, Juneja H. Association of thrombomodulin 455A/V dimorphism with risk of developing coronary heart disease. XVIIth Congress of the International Society on Thrombosis and Haemostasis, Washington DC, Aug 14-21 1999. Thromb Haemost Suppl. 538.1999.
  60. Aleksic N, Ahn C, Boerwinkle E, Juneja H, Folsom AR, Wu KK. Factor XIII V34L polymorphism and the risk for development of coronary heart disease. XVIIth Congress of the International Society on Thrombosis and Haemostasis, Washington DC, Aug 14-21 1999. Thromb Haemost Suppl. 538.1999.
  61. Afshar-Kharghan V, Aleksic N, Ahn C, Boerwinkle E, Wu KK, Lopez JA. Prospective study of the association of the variable number of tandem repeats (VNTR) polymorphism in platelet glycoprotein (GP) Ib-alpha and incidence of coronary heart disease. XVIIth Congress of the International Society on Thrombosis and Haemostasis, Washington DC, Aug 14-21 1999. Thromb Haemost Suppl. 538.1999.
  62. Wu KK, Matijevic-Aleksic N, Ahn C, Boerwinkle E, Folsom AR, Juneja H. Thrombomodulin 455A/V dimorphism is a risk factor for developing coronary heart disease in African Americans but not in Caucasians: The ARIC Study. The 41th American Society of Hematology Annual Meeting, New Orleans, Louisiana, December 3-7, 1999. Blood. 94:374.suppl.1.1999.
  63. Folsom AR, Aleksic N, Salomaa V, Park E, Juneja H, Wu KK. Fibrinolytic variables and incident CHD in the Atherosclerosis Risk in Communities (ARIC) Study. 40th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, San Diego, CA, March 1-4, 2000.Circulation. 101:721. 2000.
  64. Elezovic I, Matijevic-Aleksic N, Rolovic Z, Boskovic D, Colovic M. Hypercoagulability in patients with acute leukemia prior to therapy. 28th Congress of the International Society of Hematology, Aug 26-30, Toronto, Canada. Abstracts. 2000.
  65. Aleksic N, Ahn C, Juneja H, Boerwinkle E, Ballantyne CM, Wu KK. Effect of interaction of plasma soluble thrombomodulin (sTM) and soluble intercellular adhesion molecule-1 (sICAM-1) on predicting risk of incident coronary heart disease (CHD): The ARIC Study. The 42nd American Society of Hematology Meeting, San Francisco, CA, December 1-5, 2000. Blood. 96:11:816a.2000.
  66. Tumbusch KJ, Goldsby J, Arbab F, Matijevic-Aleksic N, Huang J-C. The expression of prostaglandin H synthase-2 and the profile of arachidonic acid metabolism by human fallopian tubes. 7th Annual Texas Forum of Female Reproduction, May 3-4, 2001, Houston, TX.
  67. Tumbusch KJ, Goldsby J, Arbab F, Matijevic-Aleksic N, Huang J-C. The expression of prostaglandin H synthase-2 and the profile of arachidonic acid metabolism by human fallopian tubes (P-466). 57th Annual Meeting of the American Society for Reproductive Medicine, Orlando, FL, October 20-25, 2001. Fertil Steril. 76 (3S-suppl):S267-268.2002.
  68. Aleksic N, Ahn C, Juneja H, Boerwinkle E, Ballantyne C, Wu KK. Effect of interaction of plasma soluble thrombomodulin (sTM) and soluble intercellular adhesion molecule-1 (sICAM-1) on predicting risk of incident coronary heart disease (CHD): The ARIC Study. XVIII Congress of the International Society on Thrombosis and Hemostasis, Paris, France, July 6-12, 2001. Thromb Haemost Suppl.2001.
  69. Aleksic N, Folsom AR, Cushman M, Heckbert SR, Tsai M, Wu KK. Soluble plasma thrombomodulin (sTM), TM genotype, and risk of venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE) Study. XVIII Congress of the International Society on Thrombosis and Hemostasis, Paris, France, July 6-12, 2001. Thromb Haemost Suppl. 2001
  70. Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, Tsai AW, Yanez ND, Rosamond WD. Prospective study of venous thromboembolism in relation to factor V Leiden and related factors: The Longitudinal Investigation of Thromboembolism Etiology (LITE) Study. XVIII Congress of the International Society on Thrombosis and Hemostasis, Paris, France, July 6-12, 2001. Thromb Haemost Suppl. 2001.
  71. Tsai A, Cushman M, Tracy RP, Heckbert SR, McGovern P, Aleksic N, Rosamond WD, Folsom AR. A prospective study of factor VIIIc and von Willebrand factor in relation to venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE) Study. XVIII Congress of the International Society on Thrombosis and Hemostasis, Paris, France, July 6-12, 2001. Thromb Haemost Suppl.2001
  72. Cushman M, Folsom AR, Wang L, Heckbert SR, White R, Aleksic N, Tsai MY, Tracy RP. Concentration of Thrombin Activable Fibrinolysis Inhibitor (TAFI), a polymorphism of the TAFI gene, and the risk of venous thrombosis in a prospective study: The Longitudinal Investigation of Thromboembolism Etiology (LITE) Study. XVIII Congress of the International Society on Thrombosis and Hemostasis, Paris, France, July 6-12, 2001. Thromb Haemost Suppl. 2001
  73. Cushman M, Folsom AR, Aleksic N, Rosamond WD, Tracy RP, Heckbert SR. Fibrin fragment D-dimer and the risk of future venous thrombosis. American Society of Hematology, 43rd Annual Meeting, December 7-11, 2001, Orlando, Florida. Blood. 98:11:755a. 2001.
  74. Wu KK, Matijevic-Aleksic N, Ahn C, Juneja H, Wang Y-W. A positive interaction between plasma thrombomodulin and fibrinogen or factor VIII in predicting incident coronary heart disease. American Society of Hematology, 43rd Annual Meeting, December 7-11, 2001, Orlando, Florida. Blood. 98:11:790a. 2001.
  75. Matijevic-Aleksic N, Ahn C, Wang W, Juneja H, Wu KK. Differential association of thrombomodulin A455V polymorphism with risk of incident coronary heart disease (CHD) and ischemic stroke: The ARIC study. American Society of Hematology, 43rd Annual Meeting, December 7-11, 2001, Orlando, Florida. Blood. 98:11:790a. 2001.
  76. Huang J-C, Wun W-S A, Goldsby JS, Matijevic-Aleksic N, Wu KK. Prostacyclin enhances embryo hatching. 57th Annual Meeting of the American Society for Reproductive Medicine, Abstracts. 2002.
  77. Matijevic-Aleksic N, Ahn C, Afshar-Kharghan V, Sweetman R, Lopez JA, Nugent DJ, Boerwinkle E, Wu KK. Coexistence of multiple hemostatic genetic risk factors does not increase risk of coronary heart disease. XIXth Congress of the International Society on Thrombosis and Hemostasis, Birmingham, UK, July 12-18. J Thromb Haemost. 1: Suppl 1. OS239. 2003.
  78. N. Matijevic, R. Radovancevic, A. Bracey, B. Radovancevic, I. Gregoric, O. Frazier. Platelet and monocyte activation in patients undergoing circulatory support with left ventricular assist devices (LVAD). XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, Switzerland, July 6-12 2007, J Thromb Haemost 2007; 5, Suppl 2; P-W-369.
  79. Matijevic N, Bracey AW, Radovancevic B, Radovancevic R, Gregoric ID, Frazier OH. Increased leukocyte-platelet interactions associated with high risk heart surgery. 12th Congress of the European Hematology Association, Vienna 9 June 2007, Book of abstracts: 1596.
  80. Bracey AW, Radovancevic R, Matijevic N, Radovancevic B, Carranza S, Gregoric I, Frazier OH. Transfusion rates and platelet activation in patients undergoing high risk cardiac surgery. 12th Congress of the European Hematology Association, Vienna 9 June 2007, Book of abstracts.
  81. Radovancevic R, Radovancevic B, Bracey A, Matijevic N, Carranza S, Gregoric I, Frazier OH. Effect of platelet activation on bleeding and transfusion rates in patients undergoing high risk cardiac surgery. Vox Sang 2007: 93 (Suppl 1):S12-3.
  82. Matijevic N, Catellier D, Wu KK, Heiss G, Folsom AR. Association of monocyte and platelet markers with peripheral arterial disease: ARIC Carotid MRI Study. 48th Cardiovascular Disease Epidemiology and Prevention Annual Conference, Colorado Springs, CO, March 11-15, 2008. Circulation Vol 117, No 11 March 18, 2008, Abstract p200, page e252
  83. Yamagishi K, Aleksic N, Hannan P, Juneja H, Folsom AR. Coagulation factors II, V, IX, X, XI, XII, plasminogen and α-2 antiplasmin and risk of coronary heart disease: a case-cohort study in ARIC. 48th Cardiovascular Disease Epidemiology and Prevention Annual Conference, Colorado Springs, CO, March 11-15, 2008. Circulation Vol 117, No 11 March 18, 2008.
Refereed Original Articles in Journals
  1. Matijevic, N., Sisic, I., Korolija, P. and Pendic, B.: Effect of Complamin® on fibrinolysis and platelet aggregation in elderly. Bilt Hematol Transf. 8: 37-43, 1980
  2. Matijevic-Aleksic, N., Petrovic, M., Vidakovic, B., Plecas, V. and Pendic, B.: Platelet function in patients treated with cytostatics. Bilt Hematol Transf. 91-96, 1985
  3. Pendic, B. and Matijevic-Aleksic, N.: Influence of cytostatics on platelet aggregation in vitro. Bilt Hematol Transf. 15-20, 1985
  4. Matijevic-Aleksic, N., Petrovic, M. and Plecas, V.: Hemostasis inhibitors in malignant diseases. Bilt Hematol Transf. 47-55, 1987
  5. Matijevic-Aleksic, N. and Jelic-Ivanovic, Z.: Effect of oral anticoagulant therapy on two commercial plasma Protein C assays. Biochimica Clinica. 23-26, 1992
  6. Elezovic, I., Matijevic-Aleksic, N. and Rolovic, Z.: Antiphospholipid syndrome - recurrent thromboses and spontaneous abortuses as a consequence of antiphospholipid antibodies. Srp Arh Celok Lek. 179-181, 1994
  7. Sanduja, S. K., Tsai, A. L., Matijevic-Aleksic, N. and Wu, K. K.: Kinetics of prostacyclin synthesis in PGHS-1-overexpressed endothelial cells. Am J Physiol. 267: C1459-66, 1994
  8. Matijevic-Aleksic, N., Sanduja, S. K., Wang, L. H. and Wu, K. K.: Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line. Biochim Biophys Acta. 1269: 167-75, 1995
  9. Matijevic-Aleksic, N., McPhedran, P. and Wu, K. K.: Bleeding disorder due to platelet prostaglandin H synthase-1 (PGHS-1) deficiency. Br J Haematol. 92: 212-7, 1996
  10. Wang, L. H., Matijevic-Aleksic, N., Hsu, P. Y., Ruan, K. H., Wu, K. K. and Kulmacz, R. J.: Identification of thromboxane A2 synthase active site residues by molecular modeling-guided site-directed mutagenesis. J Biol Chem. 271: 19970-5, 1996
  11. Ghaddar, H. M., Folsom, A. R., Aleksic, N., Hearne, L. B., Chambless, L. E., Morrissey, J. H. and Wu, K. K.: Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. Circulation. 98: 2815-21, 1998
  12. Folsom, A. R., Rosamond, W. D., Shahar, E., Cooper, L. S., Aleksic, N., Nieto, F. J., Rasmussen, M. L. and Wu, K. K.: Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 100: 736-42, 1999
  13. Salomaa, V., Matei, C., Aleksic, N., Sansores-Garcia, L., Folsom, A. R., Juneja, H., Chambless, L. E. and Wu, K. K.: Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet. 353: 1729-34, 1999
  14. Wu, K. K. and Aleksic, N.: Platelet glycoprotein polymorphism and risk for coronary heart disease. Blood Coagul Fibrinolysis. 10 Suppl 1: S63-5, 1999
  15. Xu, X. M., Sansores-Garcia, L., Chen, X. M., Matijevic-Aleksic, N., Du, M. and Wu, K. K.: Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A. 96: 5292-7, 1999
  16. Aleksic, N., Juneja, H., Folsom, A. R., Ahn, C., Boerwinkle, E., Chambless, L. E. and Wu, K. K.: Platelet Pl(A2) allele and incidence of coronary heart disease: results from the Atherosclerosis Risk In Communities (ARIC) Study. Circulation. 102: 1901-5, 2000
  17. Folsom, A. R., Wu, K. K., Rasmussen, M., Chambless, L. E., Aleksic, N. and Nieto, F. J.: Determinants of population changes in fibrinogen and factor VII over 6 years: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 20: 601-6, 2000
  18. Folsom, A. R., Aleksic, N., Park, E., Salomaa, V., Juneja, H. and Wu, K. K.: Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 21: 611-7, 2001
  19. Folsom, A. R., Aleksic, N., Ahn, C., Boerwinkle, E. and Wu, K. K.: Beta-fibrinogen gene -455G/A polymorphism and coronary heart disease incidence: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 11: 166-70, 2001
  20. Gilroy, D. W., Saunders, M. A., Sansores-Garcia, L., Matijevic-Aleksic, N. and Wu, K. K.: Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts. Faseb J. 15: 288-90, 2001
  21. Salomaa, V., Matei, C., Aleksic, N., Sansores-Garcia, L., Folsom, A. R., Juneja, H., Park, E. and Wu, K. K.: Cross-sectional association of soluble thrombomodulin with mild peripheral artery disease; the ARIC study. Atherosclerosis Risk in Communities. Atherosclerosis. 157: 309-14, 2001
  22. Wu, K. K., Aleksic, N., Ahn, C., Boerwinkle, E., Folsom, A. R. and Juneja, H.: Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease. Circulation. 103: 1386-9, 2001
  23. Aleksic, N., Ahn, C., Wang, Y. W., Juneja, H., Folsom, A. R., Boerwinkle, E. and Wu, K. K.: Factor XIIIA Val34Leu polymorphism does not predict risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 22: 348-52, 2002
  24. Arbab, F., Goldsby, J., Matijevic-Aleksic, N., Huang, G., Ruan, K. H. and Huang, J. C.: Prostacyclin is an autocrine regulator in the contraction of oviductal smooth muscle. Hum Reprod. 17: 3053-9, 2002
  25. Folsom, A. R., Aleksic, N., Catellier, D., Juneja, H. S. and Wu, K. K.: C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J. 144: 233-8, 2002
  26. Folsom, A. R., Aleksic, N., Wang, L., Cushman, M., Wu, K. K. and White, R. H.: Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. Arterioscler Thromb Vasc Biol. 22: 1018-22, 2002
  27. Folsom, A. R., Cushman, M., Tsai, M. Y., Heckbert, S. R. and Aleksic, N.: Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol. 71: 285-90, 2002
  28. Folsom, A. R., Cushman, M., Tsai, M. Y., Aleksic, N., Heckbert, S. R., Boland, L. L., Tsai, A. W., Yanez, N. D. and Rosamond, W. D.: A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood. 99: 2720-5, 2002
  29. Huang, J. C., Arbab, F., Tumbusch, K. J., Goldsby, J. S., Matijevic-Aleksic, N. and Wu, K. K.: Human fallopian tubes express prostacyclin (PGI) synthase and cyclooxygenases and synthesize abundant PGI. J Clin Endocrinol Metab. 87: 4361-8, 2002
  30. Tsai, A. W., Cushman, M., Rosamond, W. D., Heckbert, S. R., Tracy, R. P., Aleksic, N. and Folsom, A. R.: Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 113: 636-42, 2002
  31. Aleksic, N., Folsom, A. R., Cushman, M., Heckbert, S. R., Tsai, M. Y. and Wu, K. K.: Prospective study of the A455V polymorphism in the thrombomodulin gene, plasma thrombomodulin, and incidence of venous thromboembolism: the LITE Study. J Thromb Haemost. 1: 88-94, 2003
  32. Cushman, M., Folsom, A. R., Wang, L., Aleksic, N., Rosamond, W. D., Tracy, R. P. and Heckbert, S. R.: Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood. 101: 1243-8, 2003
  33. Folsom, A. R., Cushman, M., Heckbert, S. R., Rosamond, W. D. and Aleksic, N.: Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol. 56: 598-603, 2003
  34. Tsai, A. W., Cushman, M., Tsai, M. Y., Heckbert, S. R., Rosamond, W. D., Aleksic, N., Yanez, N. D., Psaty, B. M. and Folsom, A. R.: Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol. 72: 192-200, 2003
  35. Wu, K. K., Aleksic, N., Ballantyne, C. M., Ahn, C., Juneja, H. and Boerwinkle, E.: Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation. 107: 1729-32, 2003
  36. Afshar-Kharghan, V., Matijevic-Aleksic, N., Ahn, C., Boerwinkle, E., Wu, K. K. and Lopez, J. A.: The variable number of tandem repeat polymorphism of platelet glycoprotein Ibalpha and risk of coronary heart disease. Blood. 103: 963-5, 2004
  37. Delgado, R. M., 3rd, Nawar, M. A., Zewail, A. M., Kar, B., Vaughn, W. K., Wu, K. K., Aleksic, N., Sivasubramanian, N., McKay, K., Mann, D. L. and Willerson, J. T.: Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation. 109: 1428-33, 2004
  38. Huang, J. C., Wun, W. S., Goldsby, J. S., Matijevic-Aleksic, N. and Wu, K. K.: Cyclooxygenase-2-derived endogenous prostacyclin enhances mouse embryo hatching. Hum Reprod. 19: 2900-6, 2004
  39. Huang, J. C., Goldsby, J. S., Arbab, F., Melhem, Z., Aleksic, N. and Wu, K. K.: Oviduct prostacyclin functions as a paracrine factor to augment the development of embryos. Hum Reprod. 19: 2907-12, 2004
  40. Liou, J. Y., Aleksic, N., Chen, S. F., Han, T. J., Shyue, S. K. and Wu, K. K.: Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. Exp Cell Res. 306: 75-84, 2005
  41. Liou, J. Y., Lee, S., Ghelani, D., Matijevic-Aleksic, N. and Wu, K. K.: Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol. 26: 1481-7, 2006
  42. Liou, J.Y., Ellent, D.P., Lee, S., Goldsby, J., Matijevic, N., Huang, J-C., Wu, K.K. Cyclooxygenase-2 derived PGE2 protects mouse embryonic stem cells from apoptosis via EP2 and AKT. Stem Cells. 25:1096-103, 2007.
  43. Liou JY, Matijevic-Aleksic N, Lee S, Wu KK. Prostacyclin inhibits endothelial cell XIAP ubiquitination and degradation. J Cell Physiol. 212:840-848, 2007.
  44. Aleksic N, Wang Y-W W, Ahn C, Juneja HS, Folsom AR, Wu KK. Assessment of coronary heart disease risk by combined analysis of coagulation factors. Atherosclerosis. 2008 Mar 13; [Epub ahead of print] PMID: 18342864
  45. R Radovancevic, N Matijevic, Arthur W. Bracey, Branislav Radovancevic, MacArthur Elayda, Igor D. Gregoric, O.H. Frazier. Increased Monocyte Activation and Leukocyte-Platelet Interactions during Circulatory Support with Left Ventricular Assist Devices. Submitted to J Heart Lung Transp.
  46. Catellier D, Aleksic N, Folsom AR, Boerwinkle E. Atherosclerosis Risk in Communities (ARIC) Carotid MRI Flow Cytometry Study of Monocyte and Platelet Markers: Intraindividual Variability and Reliability. Clin Chem. 2008 May 29. [Epub ahead of print]
  47. Folsom AR, Aleksic N, Catellier DJ, Boerwinkle E. Correlates of platelet and leukocyte activation markers assessed by flow cytometry in a population-based sample. Accepted to Atherosclerosis.
Invited Articles in Journals
  1. Matijevic-Aleksic N, Miletic V. (1989) Platelet aggregation by monomeric and aggregated immunoglobulins. Yugoslav Med Biochem 8;3-7.
  2. Matijevic-Aleksic N, Boskovic D. Laboratory control of oral anticoagulant therapy using two different thromboplastins. Yugoslav Med Biochem (1992) 11:55-58.
  3. Wu, K.K., Matijevic-Aleksic, N. Thrombomodulin: A linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis. Ann. Med. 2000. 32; Suppl 1: 73-77. Review.
  4. Matijevic N, Wu KK. Biochemical characterization of platelet-monocyte interactions by flow cytometry. New Trends in Hematology II. 2002: 231-240.
  5. Wu KK, Matijevic-Aleksic N. Molecular aspects of thrombosis and antithrombotic drugs. Crit Rev Clin Lab Sci 2005; 42:249-277. Review.
  6. Matijevic N, Wu KK. Hypercoagulable states and strokes. Curr Atheroscler Rep. 2006 8:324-9. Review.
Non-refereed Publications
  1. Zdravkovic M, Matijevic N, Ivankovic D, Pendic B, Tubin M, Cvetkovic G.(1977) Platelet aggregation and gastrointestinal complications during therapy of rheumatic fever by acetylsalicylic acid. Proc Symp Internists Drugs Health, Subotica, 229-234.
  2. Matijevic-Aleksic N, Pajevic M, Milutinovic Dj, Tomasevic R, Pendic B. (1978) The influence of storage and temperature on some functions of platelet suspensions. Proc III Yug Hematology and Transfusiology Congress, Sarajevo, 905-909.
  3. Matijevic N, Sisic I, Korolija P, Pendic B. The effect of Complamin® on fibrinolysis and platelet aggregation in the aged subjects. (1980) Bilten Hemat Transf 8/1, 37-43.
  4. Pudar-Brankovic G, Matijevic-Aleksic N, Peric Lj, Mijalkovic D, Brankovic P. (1984) Platelet aggregation in patients with diabetes mellitus. Proc III Yug Endocrinology Congress, Novi Sad, 547.

Presentations:

  1. Pendic B, Matijevic N, Plecas V, Dragovic M. Effects of cytostatics commonly used for the treatment of acute leukemia on platelet aggregation in vitro. 6th Meeting of Yugoslav Society of Hematology and Transfusiology, Portoroz, 1976.
  2. Matijevic N, Pendic B, Zdravkovic M, Ivankovic D. The effect of aspirin on platelet aggregation in vivo and in vitro. VII Yugoslav Congress of Pharmacy, Ohrid, 1976.
  3. Matijevic N, Sisic I, Korolija P, Pendic B. Estimation of hemostasis in elderly subjects treated with Complamin®. I Yugoslav Congress of Gerontologists, Belgrade, 1977.
  4. Matijevic-Aleksic N, Pajevic M, Milutinovic Dj, Tomasevic R, Pendic B. The influence of platelet storage and temperature on platelet functions. III Yugoslav Congress of Hematology and Transfusiology, Sarajevo, 1978.
  5. Pajevic M, Matijevic N, Jelic S, Djuric D, Pendic B, Plecas V. Investigation of immunological and hemostatic parameters related to platelets transfusion in patients with malignant hemopathies. III Yugoslav Congress of Hematology and Transfusiology, Sarajevo, 1978.
  6. Pendic B, Matijevic N. Cytostatics and platelet aggregation.
    III Yugoslav Congress of Hematology and Transfusiology, Sarajevo, 1978.
  7. Matijevic N, Miletic V, Pendic B. Characteristics of platelet aggregation induced by heat-aggregated immunoglobulins. VI Yugoslav Symposium of Immunology, Tara, 1979.
  8. Matijevic N, Miletic V, Pendic B. Aggregation of human blood platelets with monomeric and aggregated immunoglobulins. II Meeting of Yugoslav Society of Hemostasis and Thrombosis, Belgrade, 1979.
  9. Jelic S, Matijevic N, Miletic V. Platelet aggregation in vitro in the presence of mixed IgG and IgM cryoglobulins. II Meeting of Yugoslav Society of Hemostasis and Thrombosis, Belgrade, 1979.
  10. Matijevic N, Petrovic M, Vidakovic B, Plecas V, Pendic B. Platelet function in cytostatics treated patients. VII Meeting of Yugoslav Society of Hematology and Blood Transfusion, Split, 1980.
  11. Matijevic-Aleksic N, Pendic B. Clinical use of platelet aggregation studies. VI Yugoslav Congress of Clinical Chemistry, Split, 1983.
  12. Matijevic-Aleksic N, Rolovic Z, Pendic B. Platelet function in patients with idiopathic thrombocytopenic purpura. IV Yugoslav Congress of Hematology and Transfusiology, Skoplje, 1984.
  13. Despotovic N, Paranos S, Matijevic-Aleksic N, Rosic D. Platelet aggregation abnormalities in patients with elevated IgE. Scientific Meeting of Serbian Academy of Sciences and Art, Division of Medical Sciences, "Specific Hypersensitivity of the Organism", Belgrade, 1986.
  14. Matijevic-Aleksic N, Petrovic M, Rajic M,Vidakovic B. Antithrombin III in patients with malignant hemopathies. V Yugoslav Congress of Hematology and Transfusiology, Maribor, 1986.
  15. Matijevic-Aleksic N, Rolovic Z. Platelet aggregation in patients with idiopathic thrombocytopenic purpura. V Yugoslav Symposium on Hemostasis and Thrombosis, Novi Sad, 1987.
  16. Matijevic-Aleksic N, Jovic B, Paranos S, Despotovic N. Influence of elevated concentrations of serum IgE on human platelet aggregation. 7th Yugoslav Congress of Clinical Chemistry, Novi Sad, 1987.
  17. Matijevic-Aleksic N, Petrovic M, Jovic B, Rajic M, Vidakovic B. Hemostasis inhibitors in patients with malignant hemopathies. VII Yugoslav Congress of Cancer, Novi Sad, 1987.
  18. Petrovic M, Matijevic-Aleksic N, Plecas V, Radulovic S. Hemostasis abnormalities in malignant diseases. XXIV Meeting of Oncology and Radiology, Belgrade, 1987.
  19. Matijevic-Aleksic N, Jelic Z, Majkic-Singh N. Protein C and oral anticoagulant therapy. II Dalmatian Meeting of Clinical Chemistry, Split, 1988.
  20. Matijevic-Aleksic N, Petrovic M, Plecas V, Vidakovic B, Panajotovic-Jovic B. Comparison of hemostatic parameters in patients with malignant diseases. IX Meeting of Yugoslav Society of Hematology and Transfusiology, Novi Sad, 1988.
  21. Matijevic N, Elezovic I, Rolovic Z. Plasma levels of thrombin-antithrombin (TAT) complex in patients with acute leukemia. VI Yugoslav Meeting of Society of Hemostasis and Thrombosis, Ljubljana, 1990.
  22. Matijevic N, Elezovic I, Rolovic Z. Plasma levels of fibrinogen and fibrin degradation products in patients with acute leukemia. VI Yugoslav Meeting of Society of Hemostasis and Thrombosis, Ljubljana, 1990.
  23. Matijevic-Aleksic N, Boskovic D, Rolovic Z. Control of oral anticoagulant therapy using two different thromboplastins. 11th International Congress on Thrombosis, Ljubljana, 1990.
  24. Matijevic-Aleksic N, Jelic-Ivanovic. Functional assay of Protein C in patients on oral anticoagulant therapy. 11th International Congress on Thrombosis, Ljubljana, 1990.
  25. Matijevic-Aleksic N, Elezovic I, Marisavljevic D, Colovic M, Rolovic Z. Thrombin-antithrombin III complex in acute leukemia. 6th Yugoslav Congress of Hematology and Transfusiology, Zagreb, 1990.
  26. Matijevic-Aleksic N, Elezovic I, Rolovic Z, Dimcic Z, Stefanovic Lj. Laboratory manifestation of a lupus-like anticoagulant: case report. VIII Yugoslav Scientific Meeting of Alergology and Clinical Immunology, Kopaonik, 1990.
  27. Matijevic-Aleksic N, Dimcic Z, Rolovic Z. Protein C and Protein S in systemic diseases. VIII Yugoslav Scientific Meeting of Alergology and Clinical Immunology, Kopaonik, 1990.
  28. Matijevic-Aleksic N, Dulic B, Rolovic Z. Markers of hemostasis activation after total hip replacement. 12th International Congress on Thrombosis, Florence, 1992.
  29. Aleksic, N., Juneja, H., Folsom, A.R., Ahn, C., Boerwinkle, E., Chambless, W., Wu, K.K. Prospective study of platelet PlA1/A2 polymorphism, platelet activation and incidence of coronary heart disease. The 40th American Society of Hematology Annual Meeting, Miami Beach, Florida, December 4-8, 1998.
  30. Wu KK, Aleksic N, Ahn C, Boerwinkle E, Folsom A, Juneja H. Association of thrombomodulin 455A/V dimorphism with risk of developing coronary heart disease. XVIIth Congress of the International Society on Thrombosis and Haemostasis, Washington DC, Aug 14-21, 1999.
  31. Aleksic N, Ahn C, Boerwinkle E, Juneja H, Folsom AR, Wu KK. Factor XIII V34L polymorphism and the risk for development of coronary heart disease. XVIIth Congress of the International Society on Thrombosis and Haemostasis, Washington DC, Aug 14-21, 1999.
  32. Wu KK, Matijevic-Aleksic N, Ahn C, Boerwinkle E, Folsom AR, Juneja H. Thrombomodulin 455A/V dimorphism is a risk factor for developing coronary heart disease in African Americans but not in Caucasians: The ARIC Study. The 41th American Society of Hematology Annual Meeting, New Orleans, Louisiana, December 3-7, 1999.
  33. Aleksic N, Ahn C, Juneja H, Boerwinkle E, Ballantyne CM, Wu KK. Effect of interaction of plasma soluble thrombomodulin (sTM) and soluble intercellular adhesion molecule-1 (sICAM-1) on predicting risk of incident coronary heart disease (CHD): The ARIC Study. 42nd American Society of Hematology Meeting, San Francisco, CA, December 1-5, 2000.
  34. Aleksic N, Ahn C, Juneja H, Boerwinkle E, Ballantyne C, Wu KK. Effect of interaction of plasma soluble thrombomodulin (sTM) and soluble intercellular adhesion molecule-1 (sICAM-1) on predicting risk of incident coronary heart disease (CHD): The ARIC Study. XVIIIth Congress of the International Society on Thrombosis and Hemostasis, Paris, France, July 6-12, 2001.
  35. Aleksic N, Folsom AR, Cushman M, Heckbert SR, Tsai M, Wu KK. Soluble plasma thrombomodulin (sTM), TM genotype, and risk of venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE) Study. XVIIIth Congress of the International Society on Thrombosis and Hemostasis, Paris, France, July 6-12, 2001.
  36. Matijevic-Aleksic N, Ahn C, Wang W, Juneja H, Wu KK. Differential association of thrombomodulin A455V polymorphism with risk of incident coronary heart disease (CHD) and ischemic stroke: The ARIC study. American Society of Hematology, 43rd Annual Meeting, , Orlando, Florida. December 7-11, 2001.
  37. Matijevic N, Wu KK. (2002) Biochemical characterization of platelet-monocyte interactions by flow cytometry. 1st Serbian Congress of Hematology, Oct 2002, Belgrade, Serbia
  38. Matijevic-Aleksic N, Ahn C, Afshar-Kharghan V, Sweetman R, Lopez JA, Nugent DJ, Boerwinkle E, Wu KK. Coexistence of multiple hemostatic genetic risk factors does not increase risk of coronary heart disease. XIXth Congress of the International Society on Thrombosis and Hemostasis, Birmingham, UK, July 12-18, 2003.
  39. N. Matijevic, R. Radovancevic, A. Bracey, B. Radovancevic, I. Gregoric, O. Frazier. Platelet and monocyte activation in patients undergoing circulatory support with left ventricular assist devices (LVAD). XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, Switzerland, July 6-12 2007.
  40. Radovancevic R, Radovancevic B, Bracey A, Matijevic N, Carranza S, Gregoric I, Frazier OH. Effect of platelet activation on bleeding and transfusion rates in patients undergoing high risk cardiac surgery. XVIIth Regional Congress of the ISBT Madrid, Jun 2007
  41. Matijevic N, Bracey AW, Radovancevic B, Radovancevic R, Gregoric ID, Frazier OH. Increased leukocyte-platelet interactions associated with high risk heart surgery. 12th Congress of the European Hematology Association Vienna, June 9, 2007.
  42. Bracey AW, Radovancevic R, Matijevic N, Radovancevic B, Carranza S, Gregoric I, Frazier OH. Transfusion rates and platelet activation in patients undergoing high risk cardiac surgery. 12th Congress of the European Hematology Association Vienna, June 9, 2007.

Contact Information

Nena Matijevic (Aleksic), Ph.D.
  • Nena Matijevic (Aleksic), PhD

  • Associate Professor, Research
    Division of Acute Care Surgery, Department of Surgery,
    The University of Texas Medical School at Houston

  • Department of Surgery

  • 6431 Fannin Street
    MSB 5.016
    Houston, Texas 77030

  • phone: (713) 500-6807
    e-mail: nevenka.matijevic-aleksic@uth.tmc.edu